Leaf Expression promises rich harvest for drug industry

Plants in growing chambers which allow all parameters to be controlled. The methodology is relatively simple and production takes as little as 12 weeks. Leaf has spent the last year perfecting these processes and now are "open for business".

Company's multimillion pound purpose-built facility becomes fully operational amidst growing interest worldwide in its potentially game-changing plant transient expression technology, Hypertrans.

Simon has over 30 years of global international experience in life sciences, including his recent roles as CEO of Stratophase and as Project Director for the design and build of the UK Government’s Cell and Gene Therapy Catapult commercial-scale GMP Manufacturing Centre in Stevenage.

Dr Steven Powell, Executive Director of Leaf Expression Systems, commented: “We are pleased to be able to attract someone with as extensive and deep experience as Simon to drive Leaf Expression Systems to the next stage in its scientific and commercial development. Leaf is a unique and innovative addition to the biopharmaceutical landscape and we look forward to a period of rapid growth.”

Simon Saxby added: “I am delighted to be joining the Leaf Expression Systems team at such an important time in the growth of the business. Leaf’s revolutionary Hypertrans technology offers a solution to the significant financial pressures being experienced by the global life sciences industry to lower the costs of new diagnostics and therapeutics, by providing an innovative way of rapidly and cost-effectively producing proteins, vaccines and complex biomolecules. Our goal is now to establish Leaf Expression Systems as a partner of choice by adding real value to the research and development programmes of our clients across the globe.”

Using tobacco plants, Leaf Expression Systems' Hypertrans expression system can rapidly and safely produce not only vaccines (polio, Blue Tongue and Zika), enzymes and antibodies but also complex molecules. They have the potential to create new biochemical pathways for bioactive chemicals such as anti-cancer drugs.